Concord Biotech Ltd

Concord Biotech Bonus Issue

Concord Biotech's board recommended a 1:1 bonus share issue from free reserves. Shareholders will consider this proposal at an upcoming postal ballot on October 24, 2026.

Concord Biotech Bonus Issue

Concord Biotech approved a 1:1 bonus issue of 10.46 crore equity shares. The board also increased the company's authorized share capital to Rs. 22 Crore.

Value

₹10.46 Cr

Concord Biotech Board Meeting Date

Concord Biotech Ltd announced a board meeting for September 23, 2026, to consider a proposal for the declaration of bonus equity shares.

Concord Biotech Business Update

Concord Biotech disclosed a successful USFDA inspection at its Valthera facility with one minor non-GMP observation. No material impact on operations or existing supplies is expected.

Concord Biotech Earnings Call Transcript: Key Takeaways

Concord reports a strong 26% revenue recovery in Q1FY27, pivoting from a challenging FY26 despite previous procurement delays.

Concord Biotech Investor Presentation: Key Takeaways

Concord Biotech reported strong Q1FY27 consolidated performance with 26% revenue growth and 31% PAT growth, driven by a 46% surge in exports and expanding market share in niche fermentation APIs.

Concord Biotech Annual General Meeting

Concord Biotech Ltd held its 41st Annual General Meeting on July 31, 2026, via video conferencing. The company summarized the proceedings and acknowledged participant queries.

Concord Biotech Q1 FY27 Results: Net Profit ₹57.7 Cr, Up 30.8% YoY

Concord Biotech Ltd reported revenue from operations of ₹257.5 Cr (+26.2% YoY) and net profit of ₹57.7 Cr (+30.8% YoY) for Q1 FY27.

Key figure

Net profit ₹57.7 Cr · +30.8% YoY

Concord Biotech Board Meeting Date

Concord Biotech will hold a Board Meeting on July 31, 2026, to consider and approve the unaudited standalone and consolidated financial results.

Concord Biotech Other Announcement

Concord Biotech Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026. This is a routine regulatory compliance disclosure under SEBI LODR.

Concord Biotech Business Update

Concord Biotech filed its BRSR for FY 2025-26, detailing ESG metrics and operations. The report is a routine compliance filing with no financial or structural impact.

Concord Biotech Annual Report

Concord Biotech Ltd filed its Annual Report for FY 2025-26. The report covers corporate overview, management reports, and financial statements ending March 31, 2026.

Concord Biotech Annual General Meeting

Concord Biotech Ltd. has issued notice for its 41st AGM on July 31, 2026. The meeting will transact financial statements, dividend, and director appointments via VC/OAVM.